PGEN · Precigen, Inc.

Summary

Precigen, Inc. reported full year 2025 financial results, including $3.4 million in PAPZIMEOS net product revenue from its first partial quarter of U.S. commercial sales, total revenues up $5.8 million year-over-year, net loss attributable to common shareholders of $429.6 million or $1.37 per share, and cash, cash equivalents, and investments of $100.4 million as of December 31, 2025.

Key takeaways

• PAPZIMEOS generated $3.4 million net product revenue in Q4 2025 following FDA approval in August 2025
• Total revenues increased $5.8 million for year ended December 31, 2025 compared to 2024
• Net loss attributable to common shareholders $429.6 million or $1.37 per basic and diluted share for 2025 vs $126.2 million or $0.47 per share in 2024
• Cash, cash equivalents, and investments totaled $100.4 million as of December 31, 2025
• PAPZIMEOS patient hub enrollment surpassed 300 patients
• CMS assigned permanent J-code J3404 to PAPZIMEOS effective April 1, 2026